The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
The world record attempt will raise money for the foundation set up in memory of the Olympic gold medallist, who died in May 2013.
In today's Newsweek, Carl talks about what the 'No' vote in the Scottish Referendum could mean for Wales and the impact of legal highs.
England manager talent spotting at Swansea City v Southampton at the Liberty Stadium